These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28939395)

  • 1. Preformulation studies with the Escherichia coli double mutant heat-labile toxin adjuvant for use in an oral vaccine.
    White JA; Haghighi C; Brunner J; Estrada M; Lal M; Chen D
    J Immunol Methods; 2017 Dec; 451():83-89. PubMed ID: 28939395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The adjuvant double mutant Escherichia coli heat labile toxin enhances IL-17A production in human T cells specific for bacterial vaccine antigens.
    Leach S; Clements JD; Kaim J; Lundgren A
    PLoS One; 2012; 7(12):e51718. PubMed ID: 23284753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study.
    Lundgren A; Bourgeois L; Carlin N; Clements J; Gustafsson B; Hartford M; Holmgren J; Petzold M; Walker R; Svennerholm AM
    Vaccine; 2014 Dec; 32(52):7077-84. PubMed ID: 25444830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant.
    Norton EB; Lawson LB; Freytag LC; Clements JD
    Clin Vaccine Immunol; 2011 Apr; 18(4):546-51. PubMed ID: 21288994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.
    Holmgren J; Bourgeois L; Carlin N; Clements J; Gustafsson B; Lundgren A; Nygren E; Tobias J; Walker R; Svennerholm AM
    Vaccine; 2013 May; 31(20):2457-64. PubMed ID: 23541621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization.
    Bernstein DI; Pasetti MF; Brady R; Buskirk AD; Wahid R; Dickey M; Cohen M; Baughman H; El-Khorazaty J; Maier N; Sztein MB; Baqar S; Bourgeois AL
    Vaccine; 2019 Jan; 37(4):602-611. PubMed ID: 30563789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying a stable bulk dmLT adjuvant formulation at a clinically relevant concentration.
    Estrada MR; Bzami A; Norton EB; White JA
    Vaccine; 2023 Feb; 41(7):1362-1367. PubMed ID: 36658044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and Protective Efficacy against Enterotoxigenic Escherichia coli Colonization following Intradermal, Sublingual, or Oral Vaccination with EtpA Adhesin.
    Luo Q; Vickers TJ; Fleckenstein JM
    Clin Vaccine Immunol; 2016 Jul; 23(7):628-37. PubMed ID: 27226279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a candidate stabilizing formulation for bulk storage of a double mutant heat labile toxin (dmLT) protein based adjuvant.
    Toprani VM; Sahni N; Hickey JM; Robertson GA; Middaugh CR; Joshi SB; Volkin DB
    Vaccine; 2017 Oct; 35(41):5471-5480. PubMed ID: 28551040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin.
    Summerton NA; Welch RW; Bondoc L; Yang HH; Pleune B; Ramachandran N; Harris AM; Bland D; Jackson WJ; Park S; Clements JD; Nabors GS
    Vaccine; 2010 Feb; 28(5):1404-11. PubMed ID: 19897067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant effect of enterotoxigenic
    Seo H; Lu T; Mani S; Bourgeois AL; Walker R; Sack DA; Zhang W
    Hum Vaccin Immunother; 2020; 16(2):419-425. PubMed ID: 31361177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural Characterization and Physicochemical Stability Profile of a Double Mutant Heat Labile Toxin Protein Based Adjuvant.
    Toprani VM; Hickey JM; Sahni N; Toth RT; Robertson GA; Middaugh CR; Joshi SB; Volkin DB
    J Pharm Sci; 2017 Dec; 106(12):3474-3485. PubMed ID: 28780391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. U-Omp19 from Brucella abortus increases dmLT immunogenicity and improves protection against Escherichia coli heat-labile toxin (LT) oral challenge.
    Coria LM; Martinez FL; Bruno LA; Pasquevich KA; Cassataro J
    Vaccine; 2020 Jul; 38(32):5027-5035. PubMed ID: 32536545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT.
    Clements JD; Norton EB
    mSphere; 2018 Jul; 3(4):. PubMed ID: 30045966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic fusions of a CFA/I/II/IV MEFA (multiepitope fusion antigen) and a toxoid fusion of heat-stable toxin (STa) and heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC) retain broad anti-CFA and antitoxin antigenicity.
    Ruan X; Sack DA; Zhang W
    PLoS One; 2015; 10(3):e0121623. PubMed ID: 25803825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. dmLT Adjuvant Enhances Cytokine Responses to T Cell Stimuli, Whole Cell Vaccine Antigens and Lipopolysaccharide in Both Adults and Infants.
    Akhtar M; Nizam NN; Basher SR; Hossain L; Akter S; Bhuiyan TR; Qadri F; Lundgren A
    Front Immunol; 2021; 12():654872. PubMed ID: 34054818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intradermal vaccination with a Pseudomonas aeruginosa vaccine adjuvanted with a mutant bacterial ADP-ribosylating enterotoxin protects against acute pneumonia.
    Baker SM; Pociask D; Clements JD; McLachlan JB; Morici LA
    Vaccine; 2019 Feb; 37(6):808-816. PubMed ID: 30638799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial.
    Qadri F; Akhtar M; Bhuiyan TR; Chowdhury MI; Ahmed T; Rafique TA; Khan A; Rahman SIA; Khanam F; Lundgren A; Wiklund G; Kaim J; Löfstrand M; Carlin N; Bourgeois AL; Maier N; Fix A; Wierzba T; Walker RI; Svennerholm AM
    Lancet Infect Dis; 2020 Feb; 20(2):208-219. PubMed ID: 31757774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with a Double-Mutant (R192G/L211A) of the Heat-Labile Enterotoxin of Escherichia coli Offers Partial Protection against Campylobacter jejuni in an Adult Mouse Intestinal Colonization Model.
    Albert MJ; Haridas S; Ebenezer M; Raghupathy R; Khan I
    PLoS One; 2015; 10(11):e0142090. PubMed ID: 26540197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection.
    Sjökvist Ottsjö L; Flach CF; Clements J; Holmgren J; Raghavan S
    Infect Immun; 2013 May; 81(5):1532-40. PubMed ID: 23439305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.